Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Genprex Inc (NQ: GNPX )

0.3900 +0.0250 (+6.85%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 463,620
Open 0.3800
Bid (Size) 0.3711 (3)
Ask (Size) 0.3900 (55)
Prev. Close 0.3650
Today's Range 0.3627 - 0.4000
52wk Range 0.2806 - 18.59
Shares Outstanding 59,409,822
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Planned Spin-Out to Focus on Gene Therapy for Type-1 and Type-2 Diabetes in Parallel to Treatments for Late Stage Lung Cancer: Genprex, Inc. (Nasdaq: GNPX)
Via Get News
Positive Clinical Results with Promising Gene Therapy Treatment for Late Stage Lung Cancer; Life-Changing Developments for Cancer and Diabetes: Genprex, Inc. (Nasdaq: GNPX)
Via Get News
Topics Intellectual Property
Exposures Intellectual Property

Performance

YTD
-95.83%
-95.83%
1 Month
-40.91%
-40.91%
3 Month
-80.98%
-80.98%
6 Month
-87.09%
-87.09%
1 Year
-97.82%
-97.82%

More News

Read More
Crude Oil Down 2%; Paysafe Shares Surge After Q2 Results
Via Benzinga
Exposures Fossil Fuels
S&P 500 Gains 1%; Home Depot Earnings Top Views
Via Benzinga
Topics Stocks
Exposures US Equities
Nasdaq Surges 200 Points; US Producer Prices Increase 0.1% In July
Via Benzinga
GNPX Stock Earnings: Genprex Reported Results for Q2 2024
Via InvestorPlace
GNPX Stock Earnings: Genprex Beats EPS for Q1 2024
Via InvestorPlace
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Clinical Trials Commenced for Promising Acclaim-3 Reqorsa® Immunogene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer: Genprex, Inc. (NASDAQ: GNPX)
Via Get News
New Company Officers Appointed After Promising Preclinical Data on Gene Therapy for Anti-Tumor Mechanisms with Ability to Trigger Cancer Cell Death: Genprex, Inc. (NASDAQ: GNPX)
Via Get News
BioMedNewsBreaks — Genprex Inc. (NASDAQ: GNPX) Announces Participation at Upcoming Investor, Industry Events
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property Product Safety
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Positive Preclinical Data Supporting NPRL2 Gene Therapy
Via Investor Brand Network
Exposures Product Safety
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Closes on $6.5M Registered Direct Offering
Via Investor Brand Network
Exposures Product Safety
TechMediaBreaks – Genprex Inc. (NASDAQ: GNPX) Closes on $6.5M Registered Direct Offering
Via Investor Brand Network
Exposures Product Safety
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
TinyGemsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces $6.5M Registered Direct Offering
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces $6.5M Registered Direct Offering
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Adds Korean Patent for Leading Drug Candidate to Growing International Patent Portfolio
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property Product Safety
Why United Natural Foods Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Preclinical Data to be Presented at Upcoming AACR Annual Meeting
Via Investor Brand Network
Exposures Product Safety
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces New Research Collaborations, Expansion of Nonclinical Programs into New Therapeutic Indications
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces New Research Collaborations, Expansion of Nonclinical Programs into New Therapeutic Indications
Via Investor Brand Network
Exposures Product Safety
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Participation at This Month’s BIO CEO & Investor Conference
Via Investor Brand Network
Exposures Product Safety
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Phase2a Expansion of Acclaim-1 Clinical Study Enrolls, Doses First Patient
Via Investor Brand Network
Exposures Product Safety
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.